Is Slno FDA approved?
Soleno Therapeutics achieved a major regulatory milestone when its flagship lead product candidate, VYKAT XR extended-release tablets, received official approval from the United States Food and Drug Administration. This landmark approval authorized the therapy specifically for the treatment of hyperphagia in patients aged four years and older diagnosed with Prader-Willi syndrome, addressing a significant unmet medical need for this rare genetic disorder. Following this regulatory green light, the company successfully transitioned into a commercial-stage pharmaceutical provider, deploying dedicated field teams to support patient adoption and market expansion. This regulatory clearance serves as the foundational asset driving the company's operational growth and commercial valuation.
Related FAQs
Class-action lawsuits involving Soleno Therapeutics, Inc.
Soleno Therapeutics Inc, trading under the ticker symbol SLNO, was a publicly traded biopharmaceutical company listed on the Nasdaq stock exchange.
Soleno Therapeutics, Inc. was originally incorporated in Delaware under the name Capnia, Inc. before undergoing a major strategic pivot and corporate rebranding.
Soleno Therapeutics operates as a fully transparent, SEC-registered public biotechnology corporation listed on major stock exchanges, adhering strictly to federal reporting standards, corporate governance rules, and pharmaceutical industry regulation...
Hyperphagia, an abnormally intense and persistent sensation of hunger often associated with rare genetic disorders like Prader-Willi syndrome, has historically relied primarily on strict environmental food security and behavioral management.
Soleno Therapeutics, Inc. maintains a specialized market capitalization valued in the tens of millions to over a hundred million U.S. dollars, reflecting its status as a clinical-stage biopharmaceutical enterprise.
Mind Medicine, commonly known as MindMed, commands a multi-billion-dollar market capitalization, reflecting high investor enthusiasm within the clinical-stage biopharmaceutical sector.
Neurocrine Biosciences completed a definitive acquisition agreement to purchase Soleno Therapeutics for a total equity valuation of approximately 2.9 billion dollars in cash.
Soleno Therapeutics Inc, trading under the ticker SLNO, is a biopharmaceutical company that has drawn significant market attention following major corporate acquisition developments and the successful commercial launch of its flagship therapeutic pro...
VYKAT XR (diazoxide choline extended-release tablets), developed by Soleno Therapeutics, received FDA approval as an essential oral treatment indicated to manage severe hyperphagia in adult and pediatric patients aged 4 years and older with Prader-Wi...
Investing in NIO involves assessing its position as an early pioneer and technology leader in premium smart electric vehicles and automated battery exchange services.
Lucid Group, traded under the ticker LCID, maintains a market capitalization fluctuating around the multi-billion-dollar range.
SmartBank operates as a growing commercial community bank serving regions across the Southeastern United States, establishing a distinct operating model when evaluated against national banking mega-corporations.
Soleno Therapeutics, Inc. reports a trailing twelve-month revenue of approximately $190.